

1 **Supplementary Materials**

2 **Khandaker et al.:** Diversity in naturally acquired immunity to Group B Streptococcus: A Comparative
3 Study of Women from Bangladesh, Malawi, and the United Kingdom

4

5 **Supplementary Methods**

6 **Ethics for the clinical study.**

7 Serum samples from Malawi were sourced from the NET-GBS study (Reference no: P.05/14/1574),
8 and the STREPCAR study (ethics no: P.07/08/686) conducted in Blantyre, Malawi, from 2008 to 2016.
9 Bangladeshi samples were obtained from women attending the Kumudini Women's Medical College
10 Hospital in Mirzapur, Bangladesh, from 2019 to 2020 (Study reference no: BICH-ERC-03-05-2018).
11 Serum samples from the UK were derived from the United Kingdom Health Security Agency
12 (UKHSA) serum collection, containing the residues of specimens submitted for diagnostic testing from
13 2015 to 2018. Ethical approval was granted by local committees from each study area and the
14 University of Liverpool Health and Life Sciences Research Ethics Committee (Ethics reference
15 number: 4797).

16

17 **Quantitation of CPS-specific IgG in sera.**

18 MagPlex microspheres (Luminex Corp) were coated with CPS-poly-l-lysine conjugates, GBS serotypes
19 Ia, Ib, II, III, IV and V (Pfizer). An 11-point standard curve, diluted 1/50 and serially diluted 2.5-fold,
20 QC samples and blank wells were included on each plate. All samples and controls were diluted into
21 assay buffer (10mMPBS/0.5% BSA/0.05% Tween/0.02% Sodium Azide, pH 7.2) and combined with
22 GBS CPS-PLL-coupled microspheres (5×10^4 microspheres/ml per serotype, 50 μ L). Samples and QC
23 samples were diluted to 1/500, 1/5000, and 1/50000.

24

25 Assay plates were mixed on an orbital shaker (MaxQ 2000 shaker, 300 RPM) and incubated overnight
26 at 4°C. The following day, plates were washed with wash buffer (1xPBS/0.05% Tween-20/0.02%
27 Sodium Azide, pH 7.2), followed by a 1.5-hour incubation with a 1/500 dilution of R-Phycoerythrin-
28 conjugated goat α -human IgG Fc γ -specific antibody (109-115-098, Jackson ImmunoResearch, UK) at

29 room temperature with agitation. After the final wash and resuspension in 100 μ L of wash buffer,
30 antigen-IgG binding was measured using a Bioplex-200 (Bio-Rad). The results were obtained as median
31 fluorescence intensities (MFIs), later converted to concentrations (μ g/ml) based on the standard curve
32 interpolation. IgG assay lower limit of quantifications (LLOQ) was assigned according to Gaylord et
33 al., 2024. (1)

34

35 **Quantitation of Alp-N-specific IgG in sera.** Serum IgG Abs to GBS surface protein antigens (Alp1-
36 N, Alp2/3-N, α C-N, and Rib-N) were quantified using ELISA. A MinervaX internal reference serum
37 was utilised as a standard with the known concentration of antibodies specific to each Alp-N protein.
38 ELISA plates were coated with 0.5 μ g/ml of relevant recombinant Alp protein (Bioneer A/S) by
39 incubating overnight at 4°C. The following day, the plates were washed and blocked with PBS-3 %
40 BSA (blocking buffer) for 1 hour at room temperature. Serum samples and MinervaX reference serum
41 were serially diluted in PBS-3 % BSA-0.05% Tween 20 (sample buffer) and added to the plates.
42 Following a 2-hour incubation at room temperature, horseradish peroxidase (HRP)-conjugated
43 detection antibody, Goat F(ab')₂ Anti-Human IgG-HRP (SouthernBiotech 2042-05), was added and
44 incubated for an additional hour at room temperature. HRP was detected using 100 μ l/well of 3, 3', 5,
45 5'-tetramethylbenzidine substrate (TMB PLUS2 ELISA HRP Substrate, Kementec 4395) and the
46 resulting colour reaction was stopped with 1 M sulfuric acid after a 30 min incubation at room
47 temperature. Absorbance readings were taken at 450 nm wavelength using a Spectrostar Nano
48 microplate reader (BMG Labtech). Quantification of antibody concentrations in serum samples was
49 performed for all sample dilutions by referencing the absorbance values obtained from the calibrated
50 MinervaX reference serum standard curves. IgG assay LLOQs (μ g/ml) for each Alp protein in this study
51 were: Alp1-N = 0.0076, Alp2/3-N = 0.01, α C-N = 0.0078, and Rib-N = 0.0042.

52

53 **Opsonophagocytosis killing assay (OPKA).** HL-60 cells (CCL-240; American Type Culture
54 Collection) were cultured in RPMI medium (Sigma Aldrich, Burlington, MA, USA) containing 2 mM
55 L-glutamine and 20% heat-inactivated foetal bovine serum (LabTech, Heathfield, UK). These cells were
56 differentiated into neutrophil-like cells over five days, maintaining a cell density of 5×10^5 cells/ml in

57 RPMI medium supplemented with 0.8% dimethylformamide (Sigma Aldrich, Burlington, MA, USA).
58 The differentiation of HL-60 cells was confirmed using flow cytometry with fluorescently labelled
59 mouse/rat anti-human monoclonal antibodies targeting cell surface markers CD11b, CD55, and CD71
60 (BioLegend). Differentiated cells meeting the criteria (>55% CD35+ and CD11b+ and <20% CD71+)
61 were used in the OPK assay.

62

63 In the OPK assay, serum samples were serially diluted in a 96-well plate and then incubated with
64 1×10^4 /well GBS serotype Ib (NCTC, 14092) for 30 minutes at 37°C. Subsequently, differentiated HL-
65 60 cells (1×10^6 /well), pre-washed in Hank's balanced salt solution (HBSS), were combined with 12.5%
66 baby rabbit complement and added to the serum-bacteria mixture. Following another 30-minute
67 incubation at 37°C, a 10µl assay mixture was plated onto COH agar, forming streaks by tilting. The
68 plates were then incubated overnight at 37°C with 5% CO₂, and the bacterial colonies were counted
69 manually or using digital image analysis methods. The killing titres were determined to be at the 50%
70 reciprocal dilution point compared to the average Colony-Forming Units (CFU) observed in serum-free
71 controls.

72

73

74

75

76

77

78

79

80

81

82

83

84

85 **Supplementary Results**

86 **Table S1: Details of selected serum samples from three countries to construct the serum pool for**
 87 **passive immunisation in mice.**

	Sample ID	CPS Ib IgG ($\mu\text{g/ml}$)	Volume taken	Final concentration (normalised with PBS)
UK	M219061	10.925	400 μl	6 $\mu\text{g/ml}$
	M190615	5.340	400 μl	
	M202044	1.771	400 μl	
Bangladesh	85138	9.798	400 μl	6 $\mu\text{g/ml}$
	87948	2.643	400 μl	
	85502	5.583	400 μl	
Malawi	672	6.727	1000 μl	6 $\mu\text{g/ml}$
	802	2.493	200 μl	

88

89

90

91

92

93

94

95

96

97 **Table S2: Geometric Mean Concentration (GMC) of IgG to CPS Ia, Ib, II, III, IV, and V of Group**
 98 **B Streptococcus in the UK, Bangladesh, and Malawi along with the inter-country comparisons of**
 99 **the IgG concentrations.**

Country	Geometric mean concentration (GMC)	95% CI	Comparator countries	Adjusted P Values*
CPS Ia				
UK	0.034	0.017-0.065	UK vs. BD	<0.0001
BD	0.929	0.533-1.617	UK vs. Malawi	0.0970
Malawi	0.011	0.006-0.018	BD vs. Malawi	<0.0001
CPS Ib				
UK	0.015	0.009-0.023	UK vs. BD	<0.0001
BD	0.099	0.063-0.154	UK vs. Malawi	>0.9999
Malawi	0.017	0.011-0.026	BD vs. Malawi	<0.0001
CPS II				
UK	0.268	0.171-0.420	UK vs. BD	<0.0001
BD	2.306	1.613-3.298	UK vs. Malawi	0.0905
Malawi	0.579	0.405-0.827	BD vs. Malawi	<0.0001
CPS III				
UK	0.047	0.029-0.076	UK vs. BD	<0.0001
BD	0.472	0.299-0.745	UK vs. Malawi	0.2558
Malawi	0.024	0.016-0.037	BD vs. Malawi	<0.0001
CPS IV				
UK	0.014	0.010-0.021	UK vs. BD	0.0011
BD	0.034	0.023-0.051	UK vs. Malawi	0.1398
Malawi	0.021	0.015-0.030	BD vs. Malawi	0.4300


	CPS V			
UK	0.012	0.008-0.018	UK vs. BD	0.0003
BD	0.032	0.020-0.050	UK vs. Malawi	0.1459
Malawi	0.014	0.011-0.020	BD vs. Malawi	0.2352

100

101 **Table S3: Geometric Mean Concentration (GMC) of IgG directed against Alp1-N, Alp2/3-N, aC-**
 102 **N and Rib-N proteins in the UK, Bangladesh, and Malawi along with the inter-country**
 103 **comparisons of the IgG concentrations.**

Country	Geometric mean concentration (GMC)	95% CI	Comparator countries	Adjusted P Value*
Alp1-N				
UK	0.087	0.071-0.108	UK vs. BD	>0.9999
BD	0.082	0.067-0.099	UK vs. Malawi	0.0156
Malawi	0.057	0.046-0.068	BD vs. Malawi	0.0391
Alp2/3-N				
UK	0.090	0.070-0.116	UK vs. BD	>0.9999
BD	0.079	0.065-0.097	UK vs. Malawi	<0.0001
Malawi	0.038	0.032-0.045	BD vs. Malawi	<0.0001
aC-N				
UK	0.070	0.055-0.089	UK vs. BD	>0.9999
BD	0.064	0.053-0.079	UK vs. Malawi	0.0294
Malawi	0.044	0.036-0.052	BD vs. Malawi	0.0346
Rib-N				
UK	0.061	0.051-0.074	UK vs. BD	0.4024
BD	0.073	0.061-0.086	UK vs. Malawi	0.3375
Malawi	0.049	0.041-0.058	BD vs. Malawi	0.0062

104



105

106 **Figure S1. Serum concentration of IgG against Tetanus Toxoid (TT) and Cytomegalovirus**
 107 **Glycoprotein B (CMV-gB) antigens in women in the UK, Bangladesh, and Malawi.**


108 The IgG concentration against TT and CMV-gB was determined using the multiplexed Luminex bead-
 109 based method. Concentrations are expressed in Mean Fluorescence Intensity (MFI).

110 Statistical significance was determined using the Kruskal-Wallis and Dann's multiple comparison tests.

111 (**p<0.01, ****p<0.0001, 'ns' used for non-significant differences). Box and Whisker plots indicate

112 median, IQR and minimum/maximum values.


113



114

115 **Figure S2. Correlation between anti-CPS Ib IgG titre and the subclasses.** Simple linear regression
 116 was performed to assess the relationship between CPS Ib-specific IgG titres ($\mu\text{g/ml}$) and subclasses
 117 (IgG1, IgG2, IgG3, and IgG4) expressed in mean fluorescent intensity (MFI). The figure illustrates the
 118 correlations, including 95% confidence bands of the best fit.

119



120


121 **Figure S3. Correlation between anti-CPS IgG titre and functional properties.** Simple linear

122 regression was performed to assess the relationship between CPS Ib-specific IgG titres ($\mu\text{g/ml}$) and

123 FcRn receptor binding, antibody-dependent complement deposition (ADCD), and opsonophagocytic

124 killing (OPK). The figure illustrates the correlations, including 95% confidence bands of the best fit.


125



126

127 **Figure S4. Correlation Between Alp Protein-Specific IgG Titres and Subclasses in Sera from the**
 128 **UK.** Simple linear regression was performed to assess the relationship between IgG titres (ng/ml) and
 129 subclasses (IgG1, IgG2, IgG3, and IgG4) expressed in mean fluorescent intensity (MFI). The figure
 130 illustrates the correlations, including 95% confidence bands of the best fit.

131



132


133 **Figure S5. Correlation Between Alp Protein-Specific IgG Titres and Subclasses in Sera from**

134 **Bangladesh.** Simple linear regression was performed to assess the relationship between IgG titres

135 (ng/ml) and subclasses (IgG1, IgG2, IgG3, and IgG4) expressed in mean fluorescent intensity (MFI).

136 The figure illustrates the correlations, including 95% confidence bands of the best fit.

137



138


139 **Figure S6. Correlation Between Alp Protein-Specific IgG Titres and Subclasses in Sera from**

140 **Malawi.** Simple linear regression was performed to assess the relationship between IgG titres (ng/ml)

141 and subclasses (IgG1, IgG2, IgG3, and IgG4) expressed in mean fluorescent intensity (MFI). The figure

142 illustrates the correlations, including 95% confidence bands of the best fit.

143



144


145 **Figure S7. Correlation between Alp Protein-Specific IgG titre and FcRn binding.** Simple linear

146 regression was performed to assess the relationship between four Alp protein-Specific IgG titre (ng/ml)

147 and FcRn binding expressed in mean fluorescent intensity (MFI). The figure illustrates the correlations,

148 including 95% confidence bands of the best fit.

149



150

151 **Figure S8. Correlation between Alp Protein-Specific IgG titre and antibody-dependent**
 152 **complement deposition (ADCD).** Simple linear regression was performed to assess the relationship
 153 between four Alp protein-Specific IgG titre (ng/ml) and antibody-dependent complement deposition
 154 (ADCD) expressed in mean fluorescent intensity (MFI). The figure illustrates the correlations, including
 155 95% confidence bands of the best fit.

156

157 **References:**

158

- 159 1. Gaylord MA, Larrier M, Giordano-Schmidt D, Grube CD, Singh S, Nguyen HH, et al.
 160 Development and validation of a 6-plex Luminex-based assay for measuring human serum antibodies
 161 to group B streptococcus capsular polysaccharides. Hum Vaccin Immunother. 2024;20(1):2311480.

